Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C6orf120 (Chromosome 6 open reading frame 120) encodes a protein of largely unknown function that is upregulated in liver hepatocellular carcinoma and serves as a potential diagnostic and prognostic marker. Bioinformatic and experimental studies suggest C6orf120 regulates tumor cell migration, promotes angiogenesis via paracrine signaling mechanisms, and modulates pathways related to metabolism, mRNA processing, and protein modification. Its expression correlates with immune cell infiltration, and it may influence macrophage polarization and immune checkpoint regulation, indicating a role in the tumor microenvironment and possible relevance for immunotherapy strategies. The precise molecular mechanism remains unclear, but the protein is part of gene networks involving other regulatory proteins and noncoding RNAs, notably within the LINC-PINT/miR-1-3p/C6orf120 axis in cancer pathogenesis. No clinically approved drugs target C6orf120 directly as of current knowledge, and its protein family is still largely uncharacterized.
mechanisms of targeted drug action are not described; however, potential regulatory axes involve noncoding RNAs and immune checkpoints
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromosome 6 open reading frame 120 (C6orf120).